TY - JOUR
T1 - Age-specific vaccination coverage estimates for influenza, human papillomavirus and measles containing vaccines from seven population-based healthcare databases from four EU countries - The ADVANCE project
AU - Braeye, Toon
AU - Emborg, Hanne-Dorthe
AU - Llorente-García, Ana
AU - Huerta, Consuelo
AU - Martín-Merino, Elisa
AU - Duarte-Salles, Talita
AU - Danieli, Giorgia
AU - Tramontan, Lara
AU - Weibel, Daniel
AU - McGee, Chris
AU - Villa, Marco
AU - Gini, Rosa
AU - Lehtinen, Matti
AU - Titievsky, Lina
AU - Sturkenboom, Miriam
N1 - Funding Information:
The Innovative Medicines Initiative Joint Undertaking funded this project under ADVANCE grant agreement n° 115557 , resources of which were composed of a financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and in kind contributions from EFPIA member companies.
Publisher Copyright:
© 2020 The Author(s)
PY - 2020/4/3
Y1 - 2020/4/3
N2 - BACKGROUND: The Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) is a public-private collaboration aiming to develop and test a system for rapid benefit-risk monitoring of vaccines using existing healthcare databases in Europe. We estimated vaccine coverage from electronic healthcare databases as part of a fit-for-purpose assessment for vaccine benefit-risk studies.METHODS: A retrospective dynamic cohort study was conducted through a distributed network approach. Coverage with measles-vaccine for birth year 2006, human papillomavirus (HPV)-vaccine for birth years 1990-2000 and influenza-vaccine for birth years 1920-1950 was estimated using period-prevalence and inverse probability weighting methods. Seven databases from four countries participated: Italy (Pedianet, Val Padana), Spain (BIFAP, SIDIAP), UK (RCGP-RSC, THIN), Denmark (SSI/AUH). Database access providers extracted the data, transformed it into a common structure and ran an R-script locally. The created output tables were shared and pooled at a central server.RESULTS: The total study population comprised 274,616 persons for measles-vaccine, 2,011,666 persons for HPV-vaccine and 14,904,033 persons for influenza-vaccine. Measles-vaccine coverage varied from 84.3% (Denmark) to 96.5% (Italy, Val Padana) for the first dose and from 82.8% (Italy, Val Padana) to 90.9% (UK) for the second dose at the age of 7 years. The HPV-vaccine coverage, aggregated over birth years 1997-2000, ranged from 60% (UK) to 88.3% (Denmark) at the age of 15 years. The influenza-vaccine coverage for the influenza seasons from 2009 to 2015 for persons aged 65 years and more was roughly stable around 43% in Denmark and around 68% in the UK while a decrease from 58 to 50% was observed in Catalonia (Spain).CONCLUSIONS: We obtained detailed, age-specific coverage estimates though a common procedure. We discussed between database comparability and comparability to published national estimates.
AB - BACKGROUND: The Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) is a public-private collaboration aiming to develop and test a system for rapid benefit-risk monitoring of vaccines using existing healthcare databases in Europe. We estimated vaccine coverage from electronic healthcare databases as part of a fit-for-purpose assessment for vaccine benefit-risk studies.METHODS: A retrospective dynamic cohort study was conducted through a distributed network approach. Coverage with measles-vaccine for birth year 2006, human papillomavirus (HPV)-vaccine for birth years 1990-2000 and influenza-vaccine for birth years 1920-1950 was estimated using period-prevalence and inverse probability weighting methods. Seven databases from four countries participated: Italy (Pedianet, Val Padana), Spain (BIFAP, SIDIAP), UK (RCGP-RSC, THIN), Denmark (SSI/AUH). Database access providers extracted the data, transformed it into a common structure and ran an R-script locally. The created output tables were shared and pooled at a central server.RESULTS: The total study population comprised 274,616 persons for measles-vaccine, 2,011,666 persons for HPV-vaccine and 14,904,033 persons for influenza-vaccine. Measles-vaccine coverage varied from 84.3% (Denmark) to 96.5% (Italy, Val Padana) for the first dose and from 82.8% (Italy, Val Padana) to 90.9% (UK) for the second dose at the age of 7 years. The HPV-vaccine coverage, aggregated over birth years 1997-2000, ranged from 60% (UK) to 88.3% (Denmark) at the age of 15 years. The influenza-vaccine coverage for the influenza seasons from 2009 to 2015 for persons aged 65 years and more was roughly stable around 43% in Denmark and around 68% in the UK while a decrease from 58 to 50% was observed in Catalonia (Spain).CONCLUSIONS: We obtained detailed, age-specific coverage estimates though a common procedure. We discussed between database comparability and comparability to published national estimates.
KW - Adolescent
KW - Age Factors
KW - Aged
KW - Alphapapillomavirus
KW - Child
KW - Cohort Studies
KW - Delivery of Health Care
KW - Europe/epidemiology
KW - Humans
KW - Influenza, Human/epidemiology
KW - Italy/epidemiology
KW - Measles
KW - Papillomaviridae
KW - Papillomavirus Vaccines
KW - Pertussis Vaccine
KW - Retrospective Studies
KW - Spain
KW - Vaccination
KW - Vaccination Coverage
KW - Influenza vaccines
KW - Measles vaccines
KW - Probability
KW - Papillomavirus vaccines
KW - Vaccination coverage
UR - http://www.scopus.com/inward/record.url?scp=85081910515&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2020.02.082
DO - 10.1016/j.vaccine.2020.02.082
M3 - Article
C2 - 32171573
SN - 0264-410X
VL - 38
SP - 3243
EP - 3254
JO - Vaccine
JF - Vaccine
IS - 16
ER -